[EN] COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE SYMPTÔMES ÉMOTIONNELS/PSYCHOLOGIQUES DANS LE SYNDROME DE L'X FRAGILE
申请人:VANDERKLISH PETER
公开号:WO2019075394A1
公开(公告)日:2019-04-18
The invention is directed, in various embodiments, to methods of treatment of the emotional or psychological symptoms of Fragile X Syndrome (FXS) in human patients by administration of an effective dose of a compound that is an inhibitor of the cortisol synthetic enzyme 11β-hydroxysteroid dehydrogenase type 1 (HSD11β1) or an effective dose of an antagonist of the corticotropin releasing hormone (CRH) receptor. For instance, an effective dose of one of these two classes of drugs is administered to a patient for treatment when the emotional and psychological symptom of FXS comprises chronic anxiety in any form, social aversion, obsessive compulsive behaviors, aggression, agitation, self injurious behavior, or any combination thereof.
Strukturabhängigkeit der antiplasmodischen Wirkung von 3-[N(4′-Amidosulfonyl)-phenyl]-aminomethyl-chinolin
Die Struktur der Titelverbindung 1 ist offenbar ein neues antiplasmodisches Wirkungsprinzip, weil weder die Chinolinkomponente, noch der Sulfonamidanteil, noch die Art der Verknüpfung ohne erhebliche Wirkungseinbuße verändert werden dürfen.